Actively Recruiting
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
Led by Samara State Medical University · Updated on 2024-12-16
105
Participants Needed
2
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will study the state of the endothelium in patients with chronic myeloid leukemia during therapy with the II generation tyrosine kinase inhibitor bosutinib. Patients will be divided into groups receiving nilotinib 800mg/day, bosutinib 500mg/day, and imatinib 600mg/day. A comprehensive examination of patients will be carried out, including a clinical examination, a study of biochemical markers of endothelial damage and the functional state of the vascular wall. An algorithm will be developed for assessing the state of endothelial function in patients with ph-positive chronic myeloid leukemia in the chronic phase when using the second-generation tyrosine kinase inhibitor bosutinib.
CONDITIONS
Official Title
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase before treatment and receiving tyrosine kinase inhibitors of first or second generation (imatinib, nilotinib, bosutinib)
- Patient provides informed consent to participate in the study
You will not qualify if you...
- History of acute cerebrovascular accident
- Previous myocardial infarction
- Presence of type I or II diabetes mellitus
- Chronic kidney disease stages C1 to C5
- Coronary heart disease with clinical symptoms (functional class II-IV)
- Hypertension grade III
- Atherosclerotic lesions of peripheral arteries detected by color duplex sonography
- Atrial fibrillation or flutter
- Presence of other cancers
- Active inflammatory diseases
- Mutations causing resistance to first or second generation tyrosine kinase inhibitors
- Patient refuses examination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
National Medical Research Centre for Hematology
Moscow, Russia
Actively Recruiting
2
Samara State Medical University
Samara, Russia
Actively Recruiting
Research Team
I
Igor Davydkin
CONTACT
S
Sabina Cherenova
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here